Objective: The objective of the study was to evaluate anti-factor Xa levels with therapeutic enoxaparin anticoagulation in pregnancy.
Introduction
Pregnancy is a hypercoagulable state. Venous thromboembolism complicates 0.05 to 0.3% of pregnancies and is the leading cause of maternal mortality in the United States. 1 Pregnant women with prosthetic heart valves are at a particular risk of thromboembolic complications because of the fluctuating requirements of anticoagulant medications, and perhaps, periods of sub-therapeutic anticoagulation. [2] [3] [4] [5] Maintenance of a steady, consistent and therapeutic level of anticoagulation is critical in the management of such patients.
Enoxaparin is considered safe and efficacious and is a commonly used anticoagulant for pregnant women with appropriate indications. 6, 7 It is a low-molecular-weight heparin (LMWH) manufactured by Sanofi-Aventis (Bridgewater, NJ, USA), and marketed as Lovenox or Clexane, which is derived from the intestinal mucosa of pigs. The standard enoxaparin dose of 1 mg/kg ± 20%, subcutaneously (s.c.) divided into a twice-daily (b.i.d.) regimen, is considered adequate for the treatment of deep vein thrombosis, pulmonary embolism and prosthetic heart valves; however, the latter group lacks sufficient data to support a universal treatment with enoxaparin. [8] [9] [10] [11] [12] The aim of therapeutic anticoagulation with enoxaparin is to achieve a peak anti-factor Xa activity level of 0.5 to 1.2 U/ml. 11 Pre-dose (trough) anti-factor Xa levels are not routinely measured. The advantages of using enoxaparin over unfractionated heparin include a more predictable dose response and a lower risk of heparin-induced thrombocytopenia and osteoporosis. 13, 14 Similar to unfractionated heparin, studies have shown that enoxaparin does not cross the placenta in any trimester, [15] [16] [17] and is primarily cleared by the kidneys. Maternal physiological increases in plasma volume and glomerular filtration rate alter enoxaparin drug levels and may lead to lower anti-factor Xa activity. 18, 19 The aim of this study was to evaluate pre-and post-dose antifactor Xa levels in pregnant patients requiring therapeutic enoxaparin at various gestational ages, and to estimate and discuss the adequacy of anticoagulation over the standard 12-h dosing interval.
Methods
Our study was a prospective, cross-sectional pilot project of 15 pregnant subjects receiving therapeutic doses of enoxaparin. The sample size was based on enrollment of all eligible subjects within a 3-year period. The study was conducted at Long Beach Memorial Medical Center/Miller Children's Hospital and the University of California, Irvine Medical Center, and was approved by the institutional review board at both institutions.
Nulliparous or multiparous women with single intrauterine pregnancies receiving b.i.d. therapeutic doses of enoxaparin (1 mg/kg±20% s.c.) were eligible to participate. Subjects receiving prophylactic doses of enoxaparin, other formulations of LMWH and those with significant renal impairment (for example, abnormal creatinine clearance) or hepatic impairment were excluded. Baseline characteristics of the patients, including body mass index (BMI) at the time of enoxaparin initiation, indication for anticoagulation and gestational age, were collected. Eligible women who consented to participate in the study continued their b.i.d. standard therapeutic dose of enoxaparin as prescribed by their primary physician. Hospitalized patients received enoxaparin from the hospital's in-patient pharmacy at Long Beach Memorial Women's Hospital or at the University of California, Irvine. Outpatients filled their prescriptions at a pharmacy of their choice. In-patients received enoxaparin dose s.c. at 0800 and 2000 hours by their nurses in accordance with the hospital drug administration policy. After receiving a minimum of three doses of enoxaparin, the first anti-factor Xa level was drawn before the fourth doseFcalled the 'pre-dose' or 'trough' level. Waiting until this time period allowed enoxaparin to reach an adequate steady state, based on an average elimination half-life of 4.5 h (range 3 to 6 h). At 3 to 4 h after the fourth dose of enoxaparin, a second antifactor Xa level was drawnFthe 'peak' level. At 8 h later, the third anti-factor Xa level was drawn. Enoxaparin dosage changes after study completion were made at the discretion of the treating physician.
Outpatients were consented at their physician's office, and were instructed to come to the General Clinical Research Center half an hour before their morning dose of enoxaparin (after a minimum of three doses for recent initiators of anticoagulation therapy). After the first blood sample for anti-factor Xa level was collected by the phlebotomist at the research center, the patient self-administered her usual dose of enoxaparin as directed by the primary physician. The patient subsequently had the second and third blood draws 3 to 4 h and 8 h later.
The blood samples obtained were centrifuged for 15 min at a speed of 3000 g. Centrifugation was performed within 1 h of sample collection. The plasma samples were analyzed in daily batches for anti-factor Xa activity by chromogenic assay at an associated laboratory of the Department of Pathology at Long Beach Memorial. A similar analysis was performed in the Department of Pathology at the University of California, Irvine. The minimum detectable limit of the used assay was 0.1 U/ml, and the linearity range was extended to 2.0 U/ml. The same assay technique was applied in both laboratories, and no laboratory-specific differences were noted. Therapeutic anti-factor Xa activity was designated as 0.5 to 1.2 U/ml. The coefficient of variation for this assay was 98% (STA Rotachrom Heparin kits. STA Analyzers, 2001, Parsimony, NJ, USA). As this was a small exploratory study to analyze possible data trends and not powered to examine causality, descriptive statistics were used to present our data: anti-factor Xa activity levels are expressed as mean ± S.D. and percentages of absolute numbers are calculated. ), and five in the morbidly obese range (BMIX35 kg/m 2 ). The mean gestational age was 19.5±8.5 weeks. In all, 10 subjects were in the second, 3 in the first and 2 in the third trimester at the time of enrollment. The most common indication for anticoagulation was deep vein thrombosis and pulmonary embolism. The enoxaparin dose and anti-factor Xa activity levels are shown in Table 2 . The mean anti-factor Xa activity levels were as follows: pre-dose 0.45 ± 0.18 U/ml, 3-to 4-h post-dose 0.9±0.25 U/ml and 8-h post-dose 0.72 ± 0.23 U/ml ( Figure 1 ). All peak levels were in the therapeutic range of anticoagulation (anti factor Xa level between 0.5 and 1.0 U/ml); however, 20% (3/15) of the 8 h and 73% (11/15) of the trough levels were sub-therapeutic (Figure 2 ). In addition, 67% (2/3) of the patients who had a sub-therapeutic anti factor Xa level at 8-h post-dose and 54% (6/11) who had a subtherapeutic trough levels were obese. None of our patients had additional complications of their disease (for example, deep vein thrombosis progressing to pulmonary embolism) or experienced adverse effects of the enoxaparin during the study period.
Discussion
Pregnancy is a hypercoagulable state. Anticoagulation failures in this high-risk population may lead to catastrophic complications. Pregnant women with mechanical heart valves are at particular risk of valve thrombosis (9%), thromboembolic complications (12 to 22%) 4, 5 and even mortality (1 to 4%). 9 Currently, there is no universally accepted explanation for these complications; however, sub-therapeutic levels of anticoagulation remain a valid concern. The use of LMWH in pregnancy with prosthetic heart valves is a subject of debate, as women may develop valve thrombosis despite adequate documented peak therapeutic anti-factor Xa activity levels. 2, 3, 12 To our knowledge, there are lack of data on steady-state plasma concentration of enoxaparin in these women. It is well known that pregnant women require 10 to 20% higher dose of LMWH for therapeutic anticoagulation, particularly in the third trimester. [19] [20] [21] These effects are mediated by the hemodynamic alterations of pregnancy mainly because of the increase in glomerular filtration rate, as enoxaparin is exclusively excreted by the kidney. 18, 19 Our study shows sub-therapeutic anti-factor Xa activity during a substantial portion of the observation period, that is, 20% of the 8-h after dosing and 73% of the trough anti-factor Xa activity levels
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E Friedrich and AB Hameed that were below the therapeutic threshold. Similar observations were made by Barbour et al. 22 who found only 9% of the trough anti-factor Xa activity levels in the therapeutic range of anticoagulation, compared with 26% in our study. The exact significance of these short periods of sub-therapeutic anticoagulation in pregnancy remains uncertain; however, it is biologically plausible that these fluctuations may contribute to anticoagulation failures. None of the patients in our study had documented anticoagulation failures; however, the sample size in our study population was likely too small to detect such cases with statistical validity. Other studies have similarly emphasized the need for frequent monitoring to assure adequacy of anticoagulation during pregnancy. 23 A recent study evaluating prophylactic use of enoxaparin in pregnancy showed a wide range of fluctuations in the enoxaparin levels (anti-factor Xa levels). 24 As in our study, the sample size of that study was not large enough to show a difference in actual thrombotic complications within the study population, but the difference prompted the researchers to question the potential effect of a similar finding in women receiving therapeutic anticoagulation. If one acknowledges that there are fluctuations not only in the total required dose of enoxaparin through the pregnancy, but also on a daily basis, a more frequent dosing interval of the same total dose, that is, enoxaparin (1 mg kg À1 ±20% s.c.) divided three times a day, may We acknowledge the limitations of our study, including its lack of power and statistical validity. The need for therapeutic anticoagulation in pregnant women is a relatively rare occurrence, and therefore we chose the time frame required to accrue subjects. We set out to expand our understanding regarding the variations in factor Xa levels through the dosing interval. This may provide an impetus for a large multicenter trial to address this important question. We realize that drug pharmacokinetics is altered by gestational age and as most of our patients were in the second trimester of pregnancy, the results cannot be applied across all gestational ages. We did not embark on stratification of patients based on gestational age or other baseline characteristics as there are too few numbers in each group to achieve meaningful results.
Most of our patients were obese, which may further affect the drug pharmacokinetics. However, anti-factor Xa levels have been shown to be comparable among non-pregnant obese and nonobese volunteers on s.c. enoxaparin. 25 There is limited information on the effect of BMI on enoxaparin anticoagulation in pregnancy. Our study underscores the possible importance of frequent monitoring of pregnant patients on enoxaparin, and although enoxaparin is preferred over unfractionated heparin because of a more predictable dose response, this benefit may not hold true in pregnancy, especially in the obese subset of a patient population. The study also raises concerns regarding the potential detrimental effect of periods of sub-therapeutic anticoagulation during the b.i.d. dosing regimen, that is, the trough and/or the 8-h post-dose antifactor Xa activity level. Although such short periods of anticoagulation have not been associated with thromboembolic complications outside of pregnancy, the effect of pregnancy on higher rates of thromboembolic complications warrants further analysis, especially in light of the well-known devastating outcomes reported in a number of women with artificial heart valves.
In summary, our study reveals a trend that a might prove to be significant in future studies. Although there is no statistical proof that sub-therapeutic trough values of enoxaparin have meaningful clinical significance, one may hypothesize that a treatment strategy consisting of more frequent dosing (standard dose divided into three times a day regimen) of LMWH to allow steady therapeutic drug levels without significant fluctuations may minimize both thrombotic and bleeding complications. The knowledge of trough anti-factor Xa activity levels may assist the clinician in determining appropriate therapeutic enoxaparin doses in this subset of the highest-risk pregnant patients. Although the current monitoring practice of peak factor Xa levels should continue, we feel that >70% of sub-therapeutic trough levels in our study warrant further analysis and may ultimately offer an explanation for the anticoagulation failures in pregnant women with mechanical heart valves. 

